

Baltimore, MD 21218

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/609,346	06/26/2003	Zailin Yu	ZYU-0603	1103
7	590 07/05/2006		EXAM	INER
FortuneRock			MERTZ, PREMA MARIA	
Attn: Dr. Zailii Apt. D109	1 Yu		ART UNIT	PAPER NUMBER
3120 Saint Paul St.			1646	

DATE MAILED: 07/05/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/609,346	YU ET AL.
Office Action Summary	Examiner	Art Unit
	Prema M. Mertz	1646
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
Responsive to communication(s) filed on 16 Ju     This action is FINAL. 2b)☑ This     Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro	
Disposition of Claims		
4)	vn from consideration.	quirement.
Application Papers		
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Examine 10.	epted or b) objected to by the liderawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) ☐ Acknowledgment is made of a claim for foreign     a) ☐ All b) ☐ Some * c) ☐ None of:     1. ☐ Certified copies of the priority documents     2. ☐ Certified copies of the priority documents     3. ☐ Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list of the certified copies.	s have been received. s have been received in Applicati ity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s)  1)  Notice of References Cited (PTO-892)	4) 🔲 Interview Summary	(PTO.413)
<ul> <li>Notice of References Cited (PTO-992)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)</li> <li>Paper No(s)/Mail Date</li> </ul>	Paper No(s)/Mail Da	

Art Unit: 1646

## **DETAILED ACTION**

1. Applicants election without traverse of Group 9 (claims 12-14, 21-23, 27-22 and 40-41) on 6/16/2006 is acknowledged. Upon further consideration, it was determined that Group 9 is composed of 2 distinct inventions. A restriction on pending claims 12-14, 21-23, 27-22, 40-41 follows.

## Restriction/Election

2. Restriction to one of the following inventions is required under 35 U.S.C. 121:

Group I. Claims 12-14, 27-33, 40-41, drawn to a polynucleotide encoding a fusion protein HSA-IL-11 of amino acid sequence set forth in SEQ ID NO:2, vector and host cell, classified in class 536, subclass 23.4.

Group II. Claims 21-23, 27-33, 40-41, drawn to a polynucleotide encoding a fusion protein HSA-GCSF of amino acid sequence set forth in SEQ ID NO:8, vector and host cell, classified in class 536, subclass 23.4.

The inventions are distinct, each from the other because of the following reasons:

Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. 806.05 for inventive groups that are directed to different products, restriction is deemed to be proper because these methods appear to constitute patentably distinct inventions for the following reasons:

Inventions I-II, are independent and distinct, each from the other, because they are products, which possess characteristic differences in structure and function and each has an independent utility that is distinct for each invention, which cannot be exchanged. Both the

polynucleotide of inventions I-II, can be used to make hybridization probes or can be used in gene therapy. However, the polynucleotides of each of Groups I-II are distinct because the polynucleotide of Group I can only be used to produce the specific protein of amino acid sequence set forth in SEQ ID NO:2 while the polynucleotide of Group II can only be used to produce the specific protein of amino acid sequence set forth in SEQ ID NO: 8.

Having shown that these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their recognized divergent subject matter as defined by MPEP § 808.02, the Examiner has *prima facie* shown a serious burden of search (see MPEP § 803). Therefore, an initial requirement of restriction for examination purposes as indicated is proper.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

## Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Prema Mertz whose telephone number is (571) 272-0876. The examiner can normally be reached on Monday-Friday from 7:00AM to 3:30PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol, can be reached on (571) 272-0835.

Application/Control Number: 10/609,346

Art Unit: 1646

Official papers filed by fax should be directed to (571) 273-8300. Faxed draft or informal communications with the examiner should be directed to (571) 273-0876.

Information regarding the status of an application may be obtained from the Patent application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Prema Mertz Ph.D., J.D.

Page 4

Primary Examiner Art Unit 1646

June 23, 2006